No Photo Available

Last Update

2016-05-01T00:00:00.000Z

This profile was last updated on .

Is this you? Claim your profile.

Wrong Gary Frashier?

Mr. Gary E. Frashier MBA PE

President, Principal and Founder

Management Associates

Direct Phone: (210) ***-****       

Get ZoomInfo Grow

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Management Associates

Background Information

Employment History

Managing Partner

Targeted Technology

Chairman and Chief Executive Officer

OSI Pharmaceuticals , Inc.

President and Chief Executive Officer

Water's Associates

Affiliations

Board Member
BioMed SA

Board Member
Metric Medical Devices Inc

Advisor
Santalis Corporation

Board Member
ViroXis Corporation

Board Member
StemBioSys , Inc.

Business Advisory Board Member
America Stem Cell , Inc.

Board Member
Boston Life Sciences , Inc.

Member, Advisory Boards
Texas Tech University

Director
Achillion Pharmaceuticals , Inc.

Fellow
Massachusetts Institute of Technology

Fellow
Sloan

Board Member
Inex Pharmaceuticals Corporation

Member
Young Presidents' Organization Inc

Education

B.S

Chemical Engineering

Texas Tech

B.S.

Chemical Engineering

Texas Tech University

M.B.A.

Massachusetts Institute

M.B.A.

Massachusetts Institute of Technology

M.S.

Management

M.I.T

Web References (177 Total References)


ViCRO - About Us

www.vicrollc.com [cached]

Gary Frashier, President and Founder, Management Associates


Board of Directors | Metric

metricmd.com [cached]

Gary E. Frashier

Board of Directors
Mr. Frashier is President and Principal of Management Associates, and he brings extensive experience in life science management, operations and transactions, having served as a CEO for twenty-four years in life sciences and specialty chemicals. Prior to the founding of Management Associates, Mr. Frashier served as Chief Executive Officer and Chairman of OSI Pharmaceuticals, and it was during his tenure at OSI that the leading genetic-based cancer drug, "Tarceva" was discovered and developed thru initial human Proof of Concept clinical trials.
...
Mr. Frashier has raised over $250 million from a combination of equity financings and other sources, has organized many collaborations and joint programs with major pharmaceutical companies, and has served as a founder of several life science companies. Prior to OSI, Mr. Frashier served as President, International, and Executive Vice President of Millipore Corporation; President and CEO of Waters Corporation, the leader in liquid chromatography; and CEO of Genex Corporation, a protein engineering company. He has participated as a founder in organizing several biotechnology companies, including Merrimack Pharmaceuticals, Inc.; Eutropics, Inc.; America Stem Cell, Inc.; and Apex BioVentures Acquisition Corporation. He currently serves on the Board of Directors of Achillion Pharmaceuticals, Inc. (NASDAQ), ViroXis Corporation, Inc., and Metric Medical Devices, Inc., and he is an Advisor to Santalis Corporation and StemBioSys. He is a Strategic Partner in SV Life Sciences LP, a major venture capital company. He has served on numerous other private and public life science company Boards, including Maxim Pharmaceuticals, Tekmira Pharmaceuticals (Canada), Apex BioVentures Acquisition Corporation, Tanox, Inc., Cytoclonal Pharmaceuticals, Exegenics Pharmaceuticals, Aderis Pharmaceuticals, and Alseres Pharmaceuticals. Mr. Frashier has a B.S. in Chemical Engineering from Texas Tech University, which has designated him a "Distinguished Engineer Graduate," and an M.B.A. from the Massachusetts Institute of Technology, where he was selected as an "Alfred P. Sloan Fellow.


This year's judges included Patrick R. ...

www.sleepreviewmag.com [cached]

This year's judges included Patrick R. Condon and Dirk Elmendorf, co-founders of Rackspace; Gary Frashier, president of Management Associates; Randall Goldsmith, investor in residence for the Texas Technology Development Center; Lorenzo Gomez III, executive director of the 80/20 Foundation; Teryn Grater of ATKG CPAs LLP; George E. Karutz Sr of Karutz Capital and Texas Research & Technology Foundation (TRTF); Norman L. Jacobson, owner of iMageDent Management and Development Services; and Peter Savas, CEO of StemBioSys Inc.


Gary E. ...

stembiosys.com [cached]

Gary E. Frashier

"StemBioSys has done an excellent job developing its unique stem cell technology. The company is ready to move to the next level." - Gary E. Frashier
Gary Frashier's skill in the development and commercialization of life sciences technologies and companies is evident in his long list of highly productive investment rounds and profitable exits.
As CEO of OSI Pharmaceuticals he oversaw the development of Tarceva, a cancer drug eventually marketed by Roche and Genentech and currently generating $1.7 billion in annual sales. OSI was acquired for $4 billion in 2010 and in addition Mr. Frashier has raised more than $250 million in equity and other sources for a wide variety of life science companies.
His executive leadership experience includes CEO and president positions with Millipore Corp., Waters Corp. and Genex Corp. Mr. Frashier has founded or co-founded several biotechnology companies including Merrimack Pharmaceuticals, Eutropics and Apex BioVentures Acquisition Corp. He serves as a director or advisor with of many of these and other life science companies.
Mr. Frashier is a strategic partner with SV Life Sciences, a major venture capital company. He also serves as president and principal of Management Associates.
Mr. Frashier holds a B.S. in chemical engineering from Texas Tech University and an M.B.A. from the Massachusetts Institute of Technology.


Gary E. ...

stembiosys.com [cached]

Gary E. Frashier

"StemBioSys has done an excellent job developing its unique stem cell technology. The company is ready to move to the next level." - Gary E. Frashier
Gary Frashier's skill in the development and commercialization of life sciences technologies and companies is evident in his long list of highly productive investment rounds and profitable exits.
As CEO of OSI Pharmaceuticals he oversaw the development of Tarceva, a cancer drug eventually marketed by Roche and Genentech and currently generating $1.7 billion in annual sales. OSI was acquired for $4 billion in 2010 and in addition Mr. Frashier has raised more than $250 million in equity and other sources for a wide variety of life science companies.
His executive leadership experience includes CEO and president positions with Millipore Corp., Waters Corp. and Genex Corp. Mr. Frashier has founded or co-founded several biotechnology companies including Merrimack Pharmaceuticals, Eutropics and Apex BioVentures Acquisition Corp. He serves as a director or advisor with of many of these and other life science companies.
Mr. Frashier is a strategic partner with SV Life Sciences, a major venture capital company. He also serves as president and principal of Management Associates.
Mr. Frashier holds a B.S. in chemical engineering from Texas Tech University and an M.B.A. from the Massachusetts Institute of Technology.

Similar Profiles

Other People with this Name

Other people with the name Frashier

Christopher Frashier
Airgas Inc

Karen Frashier
Advocate Marketing PR LLC

Robby Frashier
Bunch Marine

Phyllis Frashier
Kegler , Brown , Hill & Ritter

Travis Frashier
Motorola Solutions , Inc.

City Directory Icon

Browse ZoomInfo's Business Contact Directory by City

People Directory Icon

Browse ZoomInfo's
Business People Directory

Company Directory Icon

Browse ZoomInfo's
Advanced Company Directory